Combined Alpha-Methylacyl-Coa Racemase Inhibition And Docetaxel Treatment Reduce Cell Proliferation And Decrease Expression Of Heat Shock Protein 27 In Androgen Receptor-Variant-7-Positive Prostate Cancer Cells

Background: Disease progression in castrate-resistant prostate cancer (PCa) is most commonly driven by the reactivation of androgen receptor (AR) signaling and involves AR splice variants including ARV7.Materials and methods: We used the ARV7-positive PCa cell line, 22Rv1, to study the relationship of the PCa marker alpha-methylacyl-CoA racemase (AMACR), AR, and ARV7 in PCa.Results: Docetaxel addition but not AMACR inhibition decreased the proliferation of 22Rv1 cells. The combination of AMACR inhibition and docetaxel treatment resulted in a maximum reduction of cell proliferation. The Western blotting analysis revealed that both AR and ARV7 expression were significantly decreased with the use of charcoal-stripped serum following AMACR inhibition and docetaxel treatment. AMACR inhibition and docetaxel treatment in the charcoal-stripped serum condition reduced the proliferation of 22Rv1, possibly via the downregulation of the heat shock protein 27.Conclusion: Using cell proliferation and Western blot analysis, we demonstrated that AMACR inhibition and docetaxel treatment, under androgen deprivation conditions, significantly reduced the proliferation of ARV7 positive cancer cells and decreased the levels of AR and ARV7 expression, possibly via downregulation of heat shock protein 27. (C) 2020 Asian Pacific Prostate Society. Publishing services by Elsevier B.V.